UPDATE 1-Roche MS drug Ocrevus approved by FDA after 3-month delay

March 28 (Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay by regulators over manufacturing issues.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.